Gilead Sciences has secured the rights to Sprint Bioscience’s preclinical oncology programme for up to $400m, sending Sprint’s stock soaring by more than 110%. This deal will see Gilead hand over $14m ...
Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead Sciences for $14 million upfront, plus the chance to net up to $400 million in biobucks. Last year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback